First patients receive experimental cancer antibody in new trial
NCT ID NCT05378425
Summary
This is the first study in people testing a new antibody drug called NTX-1088. The main goal is to find a safe dose and see how the body handles the drug, both by itself and when given with another cancer immunotherapy (pembrolizumab). It is for adults with advanced solid tumors that have spread or cannot be removed by surgery and have stopped responding to available treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
-
Hadassah Medical Center
RECRUITINGJerusalem, 9574425, Israel
Contact
-
Maria Skłodowska-Curie National Research Institute of Oncology
NOT_YET_RECRUITINGWarsaw, Poland
Contact
-
Ochsner Clinic Foundation
RECRUITINGNew Orleans, Louisiana, 70121, United States
Contact
-
Sheba Medical Center
RECRUITINGRamat Gan, 5262131, Israel
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.